Surgery and recovery can temporarily change immune activity. Studies of blood or laboratory markers differ from trials measuring recurrence, and a marker change alone does not show better cancer outcomes.
Several things happen at once around an operation. Reviews describe a stress response in which injury and stress release catecholamines, prostaglandins and cortisol, and in which a short pro-inflammatory phase is followed by a prolonged anti-inflammatory phase; natural killer (NK) cells are severely affected in that period, and sympathetic stress factors, mediators including interleukin 6 and transforming growth factor beta, and myeloid-derived suppressor cells have been proposed as mediators (Horowitz and colleagues; Angka and colleagues). Wound healing adds repair signals, and anaesthesia and pain control add their own possible effects: the breast cancer anaesthesia trials were built on the premise that the surgical stress response, volatile anaesthetic and opioids impair host defence and that regional anaesthesia with propofol ameliorates all three. Most of this mechanistic evidence comes from blood measurements in patients and from mouse models, so whether the changes alter recurrence in people is a separate question that randomised trials answer best.
A real, short-lived shift in NK-cell function and suppressive signals is described by human blood studies and mouse work, which do not measure recurrence. Anaesthetic choice in breast cancer surgery was tested in two randomised trials. Sessler and colleagues analysed 2,108 women (13 hospitals, 8 countries) given regional anaesthesia with paravertebral blocks and propofol or general anaesthesia with sevoflurane and opioid analgesia: recurrence occurred in 102 of 1,043 (10%) and 111 of 1,065 (10%), hazard ratio 0.97 (95% CI 0.74 to 1.28), median follow-up 36 months; the trial stopped after a preplanned futility boundary was crossed, and persistent incisional pain did not differ. Enlund and colleagues (the Cancer and Anaesthesia study, designed to detect an advantage of at least five percentage points for propofol) recruited 1,764 women, of whom 1,670 remained for analysis, and found five-year survival of 773 of 841 (91.9%) with propofol and 764 of 829 (92.2%) with sevoflurane, hazard ratio 1.03 (95% CI 0.73 to 1.44). Neither trial detected an advantage in its specified clinical endpoint. Their confidence intervals do not prove that all anaesthetic approaches are equivalent; keep the agents, breast-cancer population, endpoint and follow-up attached.
Blocking the stress signals is a different question. In a randomised, placebo-controlled biomarker trial of 38 women with early breast cancer, 11 days of propranolol (a beta-blocker) with etodolac (a COX-2 inhibitor) from 5 days before surgery was well tolerated and changed tumour gene expression (less epithelial-to-mesenchymal transition, fewer tumour-infiltrating monocytes, more tumour-infiltrating B cells) and blood markers (smaller presurgical rises in interleukin 6 and C-reactive protein) (Shaashua and colleagues). Recurrence was not an endpoint, so this is a biomarker result and not fewer recurrences.
Timing of immunotherapy is another open question. In two mouse models of spontaneously metastatic breast cancer, immunotherapy given before removal of the primary tumour eradicated distant metastases more effectively than the same treatment given after, with sustained peripheral tumour-specific immune responses underpinning the outcome (Liu and colleagues). That supports testing the idea in people; it is not a human result. The KEYNOTE-522 regimen gives pembrolizumab with chemotherapy before surgery and alone after it to the same patients, so by design it cannot separate the benefit of the two phases (inference from the trial design).
Shares NK cell, NK-cell recognition: missing self & stress ligands, The cancer-immunity cycle.
Shares NK cell, The cancer-immunity cycle.
Shares NK cell, NK-cell recognition: missing self & stress ligands.
Shares NK cell, NK-cell recognition: missing self & stress ligands.
Shares NK cell, NK-cell recognition: missing self & stress ligands.
Shares NK cell, NK-cell recognition: missing self & stress ligands.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/